You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Overview

What is Nucala?

Nucala is an add-on treatment for adult patients with severe refractory eosinophilic asthma.

What is severe asthma?

Research has shown that not all asthma is the same. There are different types of asthma that each require different types of treatment.

Asthma can differ in its severity and in general those patients with ‘severe’ asthma find it difficult to control their daily symptoms.

These symptoms may include: wheezing, breathlessness, chest tightness and coughing.

Severe asthma patients may continue to have asthma attacks despite being treated with high doses of prescribed medications.

What is severe refractory eosinophilic asthma?

Severe refractory eosinophilic asthma is one type of severe asthma. This is a condition where eosinophils (a type of white blood cell) are present in the lungs, causing inflammation and increasing the risk of severe asthma attacks (also known as ‘exacerbations’) for that patient.

What trials have been carried out on Nucala?

A number of trials have been conducted on Nucala including two phase III trials called MENSA and SIRIUS.

  • MENSA: Mepolizumab as Adjunctive Therapy in Patients with Severe Asthma
  • SIRIUS: Steroid Reduction with Mepolizumab Study

For more information, please see the patient information leaflet (PIL) or summary of product characteristics (SPC) at the top of the page.

References:

  1. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. European Respiratory Journal 2014; 43(2):343-73
  2. Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014; 371:1198-1207.
  3. Bel EH, Wenzel SE, Thompson PJ, et al. Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma. N Engl J Med 2014;371:1189-1197.

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. If you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard .
By reporting side effects you can help provide more information on the safety of this medicine.

Nucala is a registered trademark of the GlaxoSmithKline group of companies